Qiagen and Eppendorf form alliance

Friday, 03 February, 2006

Qiagen and Eppendorf have announced that they have formed a strategic alliance that includes co-development and co-marketing of complementary and optimised products. The alliance is intended to link the brands and product lines and to ensure the highest compatibility of their products targeting the research, applied testing and molecular diagnostics.

In addition, Qiagen has acquired Eppendorf's reagent business which includes the Eppendorf's Prime nucleic acid sample preparation and PCR reagent product lines and related intellectual property. The acquired assets represent an attractive portfolio of preanalytical and nucleic acid amplification consumables as well as a very promising pipeline of proprietary technologies for nucleic acid handling, separation, purification and amplification.

Through the alliance, Qiagen and Eppendorf intend to focus on improving biological sample management and analysis. The availability of combined and optimised products should create significant benefits for customers in research, applied testing and molecular diagnostics.

Related News

Optics11 Life appoints Jacquelien ten Dam as CEO

Optics11 Life plans to accelerate its commercial growth in key markets while building strategic...

Epilepsy pioneer elected President of Aust Academy of Science

Laureate Professor Sam Berkovic — one of the world's most respected neurologists...

CSIRO announces 300+ job cuts as part of restructure

CSIRO will need to reduce roles in its Research Units by 300–350 full-time equivalent staff...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd